- Welcome
- Committees
- General Information
- Scientific Programme
- Registration/Accommodation
- Call for Abstracts
- Exhibition and Sponsorship
- Social Events
- Granada
- The Serotonin Club
- Contact Us
Scientific & Technical Secretariat
Vibo Congresos
Plaça d'Europa 17-19
Edificio Orizonia
08908 L'Hospitalet de Llobregat. Barcelona. Spain
Tel: +34 93 510 10 05
Fax: +34 93 510 10 09
Contact
Scientific Program
- Main Objectives
- Gain insight on the mechanism of action of new/old drugs
- Understand the pharmacological properties, pharmacodynamic and pharmacokinetic, of old/new drugs
- Evaluate the clinical efficacy and safety of drugs
- Unmet needs for the development of new drugs
- Bring together basic and clinical pharmacology
- Promote the cooperation between National/regional Pharmacological Societies in Europe
- Abstract Programme
Click here to see the Online Abstract Programme
where you will find information about ORAL/POSTER sessions.
- Sessions
-
PLENARY LECTURE
- Pharmacogenetics as a tool to predict drug response. Practical applications in cardiovascular therapeutics.
Prof. Tabassome Simone, Saint Antoine Hospital. Pierre et Marie Curie University (UPMC)
-
NEURO/PSYCHO-PHARMACOLOGY
- 1. The Pharmacological modulation of adult neural stem/progenitor cells
- The Pharmacological modulation of adult neural stem/progenitor cells.
Sponsor: Italian Society of Pharmacology.
-
Chairmen:
Pier Luigi Canonico, University of Novara, Italy
and Amelia Eisch, UT Southwestern Medical Center, Dallas, Texas, USA. - Speakers:
Modulation of epileptogenesis-associated neurogenesis. Michele Simonato, University of Ferrara, Italy.
Novel targets for modulation of adult neurogenesis by psychoactive drugs. Mariagrazia Grilli, University of Piemonte Orientale “Amedeo Avogadro”, Novara, Italy.
CB1 cannabinoid receptor regulation of neurogenesis and its influence in emotional behaviour. Ismael Galve-Roperth,Complutense University, Madrid, Spain.
New Horizons for New Neurons: Adult-generated Neurons and Implications for the Normal and Diseased Brain. Amelia Eisch, UT Southwestern Medical Center, Dallas, Texas, USA. - 2. Phytocannabinoid-based medicines: Promising perspectives for brain disorders
-
Phytocannabinoid-based medicines: Promising perspectives for brain disorders
Sponsor: Almirall.
Chairmen:
Vincenzo Di Marzo, Institute of Biomolecular Chemistry, CNR, Pozzuoli, Italy.
and Javier Fernández-Ruiz, Complutense University, Madrid, Spain. - Speakers:
Phytocannabinoids: ancient compounds acting on novel targets. Vincenzo Di Marzo, Institute of Biomolecular Chemistry, CNR, Pozzuoli, Italy.
Phytocannabinoid-based therapy in brain tumors. Manuel Guzmán, Complutense University, Madrid, Spain.
Phytocannabinoid-based therapy in psychiatric disorders. Daniela Parolaro, University of Insubria, Italy.
Phytocannabinoid-based therapy in neurodegeneration. Javier Fernández-Ruiz, Complutense University, Madrid, Spain.
- 3. New perspectives in the treatment of Sleep Disorders
-
New perspectives in the treatment of Sleep Disorders
Sponsor: Ferrer.
Chairmen:
Thomas Roth, Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, USA.
and Maria Antonia Quera Salva, Sleep Unit, Raymond Poincaré Hospital, Garches, France. - Speakers:
Pathophysiology of sleep disorders. Luc Staner, Clinical Sleep Research Unit, Rouffach Hospital, France.
Unmet needs in sleep disorders including comorbidities. Thomas Roth, Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, USA.
Advancements made in the development of Orexin for sleep disorders. Luis de Lecea, Stanford University School of Medicine, Palo Alto, USA.
Evaluation of GABA agonists for the treatment of insomnia; The good, the bad & the newer generation. Maria Antonia Quera Salva, Sleep Unit, Raymond Poincaré Hospital, Garches, France. - 4. Present and Future of Immunoglobulins in the Management of Neurological diseases
- Present and Future of Immunoglobulins in the Management of Neurological diseases
Sponsor: Grifols.
Chairman:
J. García Sevilla, Universitat de les Illes Balears, Spain. - Speakers:
Benefits of the IVIGs in the management of neuromuscular diseases. I. Illa (Spain).
IVIGs in chronic inflammatory demyelinating neuropathies, CIDP (ICE Study). H.P. Hartung (Germany).
Other immuno mediated neuropathies: clinical experience. E. Nobile (Italy). - 5. Second generation antipsychotics and serotonin 5HT2A receptors
-
Second generation antipsychotics and serotonin 5HT2A receptors
Sponsor: Rovi.
Chairman:
Javier Meana, University of the Basque Country, Spain. - Speakers:
Imaging the pharmacology of antipsychotics in the human brain. Gerhard Gründer, RWTH Aachen University. Germany.
Pharmacogenetic influence of 5-HT2A receptors on antipsychotic response. María J. Arranz, King's College London, United Kingdom.
Antipsychotic activity and 5HT2A-mGlu2 receptor complex signalling crosstalk. Javier Gonzalez-Maeso, Mount Sinai School of Medicine, New York, NY, United States.
Atypical antipsychotics and Dopamine D2 receptors occupancy: the role of pharmacokinetics. Ignacio Ayani, Department of Clinical Pharmacology, Laboratorios Farmacéuticos Rovi, SA. E, Spain.
-
RECEPTORS
- 1. Latest developments in Cys-loop receptor structure and function
- Latest developments in Cys-loop receptor structure and function.
Sponsor: British Pharmacological Society.
-
Chairmen:
John Peters, Neurosciences Institute, University of Dundee, Dundee UK.
and Sarah Lummis, University of Cambridge, UK. - Speakers:
Structural studies on Prokaryotic and Eukaryotic Cys-loop receptors. Chris Ulens, University of Leuven, Belgium.
Identifying the determinants of ion selectivity and single channel conductance in Cys-loop receptors. Tim Hales, University of Dundee, UK.
Probing the transmembrane domain of nicotinic acetylcholine receptors. Neil Millar, UCL, London, UK.
Cys-loop receptors in health and disease. Beate Neisler,University of Heidelberg, Germany. - 2. Biological and therapeutic roles of glycine receptors
- Biological and therapeutic roles of glycine receptors.
Sponsor: British Pharmacological Society.
-
Chairman:
Robert J. Harvey , Department of Pharmacology, The School of Pharmacy, London, UK. -
Speakers:
Pathomechanisms of glycine receptor channelopathies and regeneration of synaptic plasticity. Carmen Villmann, Institut für Biochemie, Universität Erlangen-Nürnberg, Germany.
Glycine receptor α2 or α3 subtypes control pain, rhythmic breathing and locomotor activity. Robert J Harvey, Department of Pharmacology, The School of Pharmacy, London, UK.
A novel role for the glycine receptor α4 subunit in spinal and hindbrain control of startle and motility. Maximiliano Suster, Sars International Centre, Bergen, Norway.
Mechanisms of glycine receptor α1β subtype dysfunction in startle disease Trevor G Smart , Department of Neuroscience, Physiology & Pharmacology, University College London, UK. - 3. Rho/Rho-kinase signalling in health and diseases
- Rho/Rho-kinase signalling in health and diseases.
Sponsor: Turkish Pharmacological Society.
-
Chairman:
Kansu Buyukafsar, Mersin University, Turkey. -
Speakers:
A deep insight into the smooth muscle cell contraction in terms of Rho/Rho-kinase pathway. Avril V. Somlyo,University of Virginia, USA.
Role of Rho/Rho-kinase pathway in cardiovascular system. Hiroaki Shimokawa, Tohoku University, Japan.
Rho/Rho-kinase signalling in respiratory system. A. Tuncay Demiryurek, Gaziantep University, Turkey.
Rho-family GTPases, Rac1 and Cdc42 in ovarian cancer. Angela Wandinger-Ness,University of New Mexico, USA.
Importance of Rho/Rho-kinase pathway in gastrointestinal and urogenital systems. Kansu Buyukafsar, Mersin University, Turkey. - 4. Novel targeting of the 5-HT3 for potential therapeutic benefit
- Novel targeting of the 5-HT3 for potential therapeutic benefit
Sponsor: British Pharmacological Society. -
Chairman:
Nicholas Barnes, University of Birmingham Medical School, UK. -
Speakers:
Background to 5-HT3 receptors and therapeutic potential of this molecular target.
John Peters, Neurosciences Institute, University of Dundee, Dundee UK.
Potential of 5-HT3 receptor isoform-selective antagonists. Beate Niesler, Department of Human Molecular Genetics, University of Heidelberg, Germany.
Partial 5-HT3 receptor agonists. Bruce Sargent, AMRI Inc, Albany, New York, USA.
Allosteric modulation of the 5-HT3 receptor. Nicholas Barnes, University of Birmingham Medical School, UK. - 5. Molecular Pharmacology, towards the understanding of biased agonism
- Molecular Pharmacology, towards the understanding of biased agonism
Sponsor: Danish Society of Pharmacology.
-
Chairman:
Mette M. Rosenkilde, University of Copenhagen, Denmark. -
Speakers:
Functional selectivity and biased receptor signaling. Terry Kenakin, Glaxo SmithKline, UK.
Ligand-directed trafficking of the opiod receptors. Brigitte L. Kieffer, Université Louis Pasteur, France, Research Director at INSERM.
Biased agonism within the ghrelin receptor. Birgitte Holst Copenhagen University, Denmark.
Biased signaling within the chemokine receptor signaling. Mette M. Rosenkilde, Copenhagen University, Denmark.
Structural and functional properties of the A2A-receptors-towards biased agonism.
Ad Ijzerman, University of Leiden, The Netherlands. - 6. TRP channels
- TRP channels
Sponsor: German Society of Pharmacology.
-
Chairman:
Thomas Wieland (Germany) -
Speakers:
TRP channels as regulators of blood pressure and fertility. Marc Freichel, Department of Pharmacology, University of Heidelberg, Germany.
A TR(i)P to Magnesium Homeostasis. Thomas Gudermann, Walther-Straub-Institut fuer Pharmakologie und Toxikologie, Ludwig-Maximilians-Universitaet Muenchen, Germany.
Molecular regulation of TRPV4 channel. Miguel A. Valverde, Laboratory of Molecular Physiology and Channelopathies, Dept. Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
Recent insights on the physiological role of TRPM4. Rudi Vennekens, Laboratory of Ion Channel Research, Division of Physiology, Department Moleculaire Celbiologie, KULeuven, Belgium.
-
CARDIOVASCULAR PHARMACOLOGY
- 1. The carotid body: target for new drugs and advanced therapies
- The carotid body: target for new drugs and advanced therapies.
Sponsor: The Portuguese Society of Pharmacology.
-
Chairman:
Maria Emília Monteiro, University of Lisbon, Portugal. - Speakers:
Oxygen sensing and metabolic disturbances. Sílvia Conde, University of Lisbon, Lisbon, Portugal.
Hypertension in chronic intermittent hypoxia/obstructive sleep apnoea. Peter W de Leeuw, University Hospital Maastricht, The Netherlands.
Cell therapy in Parkinson disease. Ricardo Pardal, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla, Spain.
Carotid body chemoreception in heart failure. Harold D. Schultz, Department of Cellular & Integrative Physiology, College of Medicine, University of Nebraska, Omaha, Nebraska, USA. - 2. Organic nitrates from molecular mechanisms to clinic implications
-
Organic nitrates from molecular mechanisms to clinic implications
Sponsor: Actavis.
Organizer:
Prof. Dr. Hartmut Kleinert
-
Chairmen:
Ulrich Förstermann and Hartmut Kleinert. -
Speakers:
New insights into bioactivation and effects of organic nitrates, nitrate tolerance and cross-tolerance. A. Daiber Johannes Gutenberg University Hospital, 2nd Medical Clinic, Molecular Cardiology, Mainz, Germany.
Mechanisms of action of organic nitrates: a clinician´s perspective. T. Gori, Johannes Gutenberg University Hospital, 2nd Medical Clinic, Molecular Cardiology, Mainz, Germany.
Differential effects of organic nitrates on endothelial progenitor cells. T. Thum, Department of Cardiology and Angiology, Hannover Medical School , Hannover Germany.
Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors
C. Delgado, Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Madrid. - 3. Novel targets in the control of vascular function
-
Novel targets in the control of vascular function
Sponsor: University of Granada.
Chairmen:
Ulrich Förstermann, Johannes Gutenberg University, Mainz, Germany and
Juan Duarte, University of Granada, Spain. -
Speakers:
Pharmacological approaches and mechanisms to prevent vascular oxidative stress. Ulrich Förstermann, Johannes Gutenberg University, Mainz, Germany.
From receptor modulators to microRNAs: new therapeutic targets for vascular function. Chantal Dessy, Université Catholique de Lovain, Bruxelles.
Role of PPARβ in vascular tone in hypertension. Rosario Jiménez, University of Granada, Spain.
Perivascular adipose tissue; an emerging target for blood vessel modulation.
Arthur Weston, University of Manchester, UK. - 4. Protective agents against myocardial ischemia/reperfusion injury
-
Protective agents against myocardial ischemia/reperfusion injury
Chairman:
Alain Berdeaux.Creteil, France and Juan Tamargo, Complutense University, Madrid, Spain -
Speakers:
Twenty five years of pre/postconditioning: what lessons for a pharmacological approach of cardioprotection. Alain Berdeau, Creteil, France.
The late sodium current as a new therapeutic target in myocardial ischemia and arrhytmias. Juan Tamargo, Complutense University, Madrid, Spain.
Mitochondria as a pharmacological target for cardioprotection. David García-Dorado, Barcelona, Spain.
Mild hypothermia and cardioprotection: pharmacological and therapeutic applications
Renaud Tissier, Department of Pharmacology, Medicine faculty of Créteil and Inserm Unit U955, Paris-East University, France.
-
ENDOCRINOLOGY AND METABOLISM
- 1. New Pharmacological approaches to complex diseases: Obesity, Metabolic Syndrome and T2DM
-
New Pharmacological approaches to complex diseases: Obesity, Metabolic Syndrome and T2DM
Sponsor: University of Granada
Chairman:
Juan Carlos Laguna, Pharmacology Unit, School of Pharmacy, University of Barcelona, Spain - Speakers:
BAT activation as a therapeutic strategy for obesity and associated complications. Antonio Vidal-Puig, University of Cambridge, UK.
New compounds raising HDL by interacting directly with CETP. Eric Niesor, Pharmaceutical Division, Hoffman la Roche, Switzerland.
New drugs for T2DM: SGLT2 inhibitors. Francisco Tinahones, Universidad de Málaga, Spain.
FGF21 as a new drug-target for metabolic diseases. Dr. Francesc Villarroya, Dept. Biochemistry and Molecular Biology, Univ. of Barcelona, Spain. - 2. Antidiabetic treatments and the brain
-
Antidiabetic treatments and the brain
Sponsor:MSD Denmark
-
Introduction: Are there common denominators for metabolic diseases and neurodegeneration and can we treat them?
Chairman:
Prof. Jørgen Rungby, University of Aarhus, Denmark. -
Speakers:
DPP---IV inhibitors and GLP---1 analogues, is the brain a target?
Carolyn F Deacon, University Of Copenhagen, Denmark.
Insulin treatment and weight, can pharmacologically induced weight gain be avoided?
Manfred Hallschmid, University of Luebeck, Germany.
Cerebrovascular disease and antidiabetic treatments..
Kaare Haurvig Palnum, Aarhus University Hospital, Denmark.
- 3. New frontiers in incretin based drugs for the treatment of Diabetes Mellitus
-
New frontiers in incretin based drugs for the treatment of Diabetes Mellitus
Sponsors: Spanish Society of Pharmacology and Lilly
-
Chairmen:
Michaela Diamant, Amsterdam, The Netherlands, and
Javier Salvador, Clínica Universidad de Navarra. Pamplona, Spain.
-
Speakers:
The Pharmacologic Basis of incretin action. Differences Among GLP-1 Receptor Agonists and DPP-4 Inhibitors.
Michaela Diamant, Department of Internal Medicine, VU University Medical Center (VUMC) Amsterdam, The Netherlands.
The Role of Incretins in Glucose Homeostasis and Diabetes treatment.
Manel Puig, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain.
Role of Incretin hormones in the central control regulation of energy balance and metabolism.
Carlos Dieguez, Department of Physiology, School of Medicine, CIMUS-University of Santiago de Compostela, Spain.
Extrapancreatic effects of incretin-based therapy.
Javier Salvador, Endocrinology and nutrition Unit, Clínica Universidad de Navarra, Pamplona.
-
PHARMACOLOGY OF PAIN AND INFLAMMATION
- 1. Botulinum toxin type-A and pain
- Botulinum toxin type-A and pain
Sponsor: Croatian Pharmacological Society
-
Chairman:
Zdravko Lackovic, University of Zagreb School of Medicine, Croatia. - Speakers:
Clinical application of Botulinum toxinA in pain: where we are now?. Maja Relja, Movement Disorders Center Department, University of Zagreb, School of Medicine, Croatia.
Behavioural evidence for central origin of the antinociceptive action of Botulim toxin type A. Lidija Bach-Rojecky, Faculty of Pharmacy and Biochemistry, University of Zagreb, Croatia.
Modulatory action of Botulinum toxin type A on neuropatic pain: behavioral and immunohistochemical studies in animal models. Siro Luvisetto, Institute of Neuroscience Psychobiolog and Psychopharmacology, Roma, Italy.
Recent histochemical and physiological evidences for central effects of Botulinum toxin type A. what we know and what we dont know?. Zdravko Lackovic, Department of Pharmacology & Croatian Brain Research Institute, University of Zagreb, School of Medicine, Croatia. - 2. Novel targets for treatment of inflammatory diseases
- Novel targets for treatment of inflammatory diseases
Sponsor: Italian Society of Pharmacology
-
Chairmen:
Carlo Riccardi, University of Perugia, Italy, and Thomas Brunner, University of Konstanz, Germany. -
Speakers:
Anti-inflammatory GPCRs as novel targets to harness the resolution of inflammation. Mauro Perretti, William Harvey Research Institute, Barts and The London School of Medicine, UK.
Nuclear receptors as new targets for inflammation. Salvatore Cuzzocrea, University of Messina, Italy.
Anti-inflammatory effects of antibiotics. Mª Elena Rodriguez, CIBERehd-Department of Pharmacology, University of Granada, Spain.
Local glucocorticoid synthesis as a regulatory mechanism and therapeutic target in inflammatory bowel disease. Thomas Brunner, University of Konstanz, Germany. - 3. Sigma-1 receptors: A new target for pain treatment
-
Sigma-1 receptors: A new target for pain treatment
Sponsor:Esteve
Chairman:
José M. Baeyens, University of Granada, Spain. -
Speakers:
Potentials of selective or non-selective sigma-1 ligands in drug development programs. Tangui Maurice. INSERM U. University of Montpellier, France.
Sigma-1 receptor blockade enhances opioid-induced antinociception José M. Baeyens, University of Granada, Spain.
Sigma-1 receptor agonists and central sensitization mechanisms. Jang-Hern Lee. College of Veterinary Medicine, Seoul National University, South Korea.
Selective sigma-1 receptor antagonists: an emerging strategy for the treatment of neuropathic pain. José M. Vela. Drug Discovery and Preclinical Development, Esteve. Barcelona, Spain. - 4. Symptomatic slow acting drugs for osteoarthritis: what’s the evidence?
-
Symptomatic slow acting drugs for osteoarthritis: what’s the evidence?
Sponsor: Bioiberica Farma
Chairmen:
Maribel Lucena, Hospital Universitario Virgen de la Victoria, Facultad de Medicina, Universidad de Málaga, Spain, and
Antonio García, Facultad de Medicina, Universidad Autónoma de Madrid, Spain.
-
Speakers:
Welcome and introduction.
Maribel Lucena / Antonio García
The pathophysiology of osteoarthritis and treatment. Pascal Richette. Rheumatology Department of Rheumatology Lariboisière Hospital Paris (Paris, France).
Chondroitin sulfate: review of clinical efficacy. Antonio García, Facultad de Medicina, Universidad Autónoma de Madrid (Madrid, Spain).
Treatment of knee osteoarthritis in patients with moderate-to-severe pain. Jordi Monfort. Hospital del Mar de Barcelona (Barcelona, Spain). - 5. Novel mechanisms and molecules for the treatment of inflammation
- Novel mechanisms and molecules for the treatment of inflammation
Sponsor: Finish Society of Pharmacology.
Chairman: Eeva Moilanen (Finland)
- Speakers:
JAK3 pahway as a pathological factor and therapeutic target the in rheumatoid arthritis.
PDE4 inhibitors in the treatment of COPD and other obstructive pulmonary diseases.
Klaus Rabe, Germany.
MAP kinase phosphatases as novel ant-inflammatory treatment modalities.
Riku Korhonen, Finland.
Adipokines as inflammatory mediators. Katriina Vuolteenaho, Finland. - 6. Inflammation: a therapeutic target in numerous diseases
- Inflammation: a therapeutic target in numerous diseases.
Sponsor: Spanish Society of Pharmacology.
Chairmen: Juergen Eckel (German Diabetes Center, Duesseldorf, Germany) and
Josep Verges (BIOIBERICA, Barcelona, Spain). - Speakers:
Inflammation and atherosclerosis, role of phosphodiesterases.
Panayotis Fantidis, Unidad de AngiologÌa y CirugÌa Vascular, Hospital San Pedro de Alcantara-Complejo Hospitalario de C·ceres, Spain.
Inflammation and muscular insulin resistance: role of exercise.
Juergen Eckel, Integrative Physiology, Paul-Langerhans-Group, German Diabetes Center, Duesseldorf, Germany.
Inflammation and cancer, a target?.
Marita Hernandez, Instituto de Biología y Genetica Molecular, CSIC-Universidad de Valladolid, Valladolid, Spain.
Inflammation in osteoarthritis and the brain: role of NF-kappa β.
Josep Verges, BIOIBERICA, Barcelona, Spain.
-
RESPIRATORY AND GASTROINTESTINAL PHARMACOLOGY
- 1. New perspectives in the role of bronchodilators for the treatment of airway diseases
- New perspectives in the role of bronchodilators for the treatment of airway diseases
Sponsor: Almirall.
Organizer: Amadeu Gavaldà & Montse Miralpeix
-
Chairmen:
Montse Miralpeix, Almirall, R&D Center, Barcelona, Spain, and Maria G. Belvisi, Imperial College London. - Speakers:
New long acting muscarinic antagonists (LAMA): from preclinical to the clinical setting. Clive Page. Sackler Institute of Pulmonary Pharmacology. King's College, London, UK.
Long acting beta2 adrenergic agonists (LABA): what is coming and future hurdles. Malcolm Johnson. Respiratory Science, GlaxoSmithKline, UK.
The discovery of dual muscarinic antagonist & beta2 adrenergic agonist compounds (MABA): a path for the development of triple therapies for COPD. Montse Miralpeix, Respiratory Therapeutic Area-Discovery, Almirall, R&D Center, Barcelona
Potential novel bronchodilator mechanisms for the future. Maria G. Belvisi, National Heart & Lung Institute. Imperial College, London, UK. - 2. New therapies for pulmonary hypertension
- New therapies for pulmonary hypertension
Sponsor: Danish Society of Pharmacology
-
Introduction. Unmet needs for treatment of pulmonary hypertension.
Ulf Simonsen, Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Denmark
Chairmen:
Roger Wadsworth, Stratchclyde University, Glasgow, Scotland, Ulf Simonsen, Aarhus University, Denmark. -
Speakers:
Role of impairment of endothelial cell function in pulmonary hypertension. Roger Wadsworth, Stratchclyde University, Glasgow, Scotland.
New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Robert Najie, Free University of Brussels, Belgium.
Treatment of right ventricular heart failure. Dr. Jan Harm Bogaard, VU Medisch Centrum, Amsterdam, The Netherlands. - 3. Respiratory pharmacology and pulmonary surfactant
-
Respiratory pharmacology and pulmonary surfactant
Sponsor: Chiesi
Chairman:
Jesús Pérez-Gil, Universidad Complutense, Madrid, Spain. -
Speakers:
From biophysics to pharmacology: understanding pulmonary surfactant mechanisms to treat respiratory pathologies. Jesús Pérez-Gil, Universidad Complutense Madrid, Spain.
Rescuing premature babies with exogenous pulmonary surfactant: a tale of success. Tore Curstedt, Karolinska Institut, Stockholm, Sweden.
Surfactant for treatment of acute respiratory distress and chronic interstitial lung diseases: rationale, proof of concept and clinical experience (30 min). Andreas Gunther, Giessen University, Germany.
Pulmonary surfactant and lung transplantation. Cristina Casals, Universidad Complutense, Madrid, Spain. - 4. Interfering with the crosstalk between immune cells in gastrointestinal disorders
-
Interfering with the crosstalk between immune cells in gastrointestinal disorders
Sponsor: University of Granada
-
Chairman:
Julio Gálvez, Department of Pharmacology, University of Granada (Spain). -
Speakers:
The unfolded protein response and intestinal epithelial homeostasis. Gijs R Van den Brink. Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands.
Therapeutic targets for chronic inflammatory intestinal diseases. Where are we and what is the future? Eduard Stange. Department of internal Medicine I, Robert Bosch Hospital, Sttutgart, Germany.
Neutrophils at the interface between innate and adaptive immunity Marco Cassatella. Department of Pathology and Diagnostics, Division of General Pathology, University of Verona, Italy.
Educating the immune system with mesenchymal stem cells: a therapeutic opportunity for inflammator bowel diseases. Mario Delgado. Instituto de Parasitologia y Biomedicina "López-Neyra", CSIC. Granada. Spain.
-
PHARMACOGENOMICS
- 1. Pharmacogenetics: from drug development to clinical practice
-
Pharmacogenetics: from drug development to clinical practice
Sponsor: Instituto Roche.
Chairman:
Julio Benítez, University of Extremadura Medical School & Infanta Cristina University, Badajoz, Spain - Speakers:
Drug metabolism within the brain and drug response. Rachel Tyndale, Centre for Addiction and Mental Health, University of Toronto, Department of Pharmacology & Toxicology, Toronto, Ontario, USA.
Rational study designs for pharmacogenetics in clinical research. Julia Stingl, University Ulm, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany.
Pharmacogenomics and drug safety. Munir Pirmohamed, The Wolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, UK.
Pharmacogenetics role in clinical practice. Julio Benítez, University of Extremadura Medical School & Infanta Cristina University, Badajoz, Spain. - 2. Personalized medicine: from concept to reality
-
Personalized medicine: from concept to reality
Sponsor: Bioiberica.
Chairmen:
Ingrid Möller, Instituto Poal de Reumatología, Barcelona, Spain
and Teresa Tejerina, Universidad Complutense de Madrid, Spain. - Speakers:
Role of genetics in prediction of osteoporosis risk. Adolfo Díez, Hospital del Mar de Barcelona, Spain.
Arthrosischip: a DNA-based prognostic test for osteoarthritis. Ingrid Möller, Instituto Poal de Reumatología, Barcelona, Spain.
Wet Biomarkers for osteoarthritis diagnostic and prevention. Yves Henrotin, Department University of Liege Institute of Pathology Bone and Cartilage Research Unit CHU, Liege, Belgium.
Cell therapy: a novel pharmacological approach. Natividad Cuende, Iniciativa Andaluza en Terapias Avanzadas, Sevilla, Spain.
-
TEACHING
- 1. Teaching pharmacology to medical students
- Teaching pharmacology to medical students
Sponsor: EPHAR
-
Chairmen:
Ewan Macdonald (Kupio, Finland) and Thomas Griesbacher (Graz, Austria). - Speakers:
Teaching the WHO Guide to Good Prescribing. Emilio Sanz, Universidad de La Laguna, Spain.
Prevention of medication errors: teaching and training. Robert Likic, Zagreb, Croatia.
Teaching safe and effective prescribing to medical students. Simon Maxwell, Edinburgh, UK.
Integrating teaching of basic and clinical pharmacology. Ulf Simonsen, Aarhus, Denmark. - 2. Standards for PhD education in Biomedicine
- Standards for PhD education in Biomedicine
Sponsor: EPHAR
-
Chairmen:
Nick Goulding, London, UK, and Roland Johnsson, University of Bergen, Norway. - Speakers:
PhD programmes in Spain. Dolores Prieto, Departamento de Fisiología, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.
PhD programmes in Germany. Katrin Offe, TUM Medical Graduate Center, Faculty of Medicine, Technical University Munich, Germany.
PhD programmes in Former Eastern Europe. Zdravko Lackovic, University of Zagreb School of Medicine, Croatia.
ORPHEUS-AMSE- WFME Standards for PhD education. Michael Mulvany, Dpt.of Pharmacology, Institute of Biomedicine, Aarhus University, Aarhus, Denmark.